Certara (NASDAQ:CERT – Get Rating) updated its FY 2022 earnings guidance on Tuesday. The company provided EPS guidance of $0.43-$0.48 for the period, compared to the consensus EPS estimate of $0.50. The company issued revenue guidance of $325.00 million-$335.00 million, compared to the consensus revenue estimate of $355.09 million.

Analyst Ratings Changes

A number of research firms have recently issued reports on CERT. SVB Leerink cut their target price on shares of Certara from $29.00 to $26.00 and set an outperform rating for the company in a research note on Wednesday, August 10th. Berenberg Bank assumed coverage on shares of Certara in a research report on Thursday. They set a buy rating and a $23.00 price target on the stock. Morgan Stanley lowered their price target on shares of Certara from $24.00 to $20.00 and set an equal weight rating on the stock in a research report on Wednesday, August 24th. Barclays lowered their price target on shares of Certara from $24.00 to $21.00 and set an overweight rating on the stock in a research report on Wednesday, August 17th. Finally, Credit Suisse Group assumed coverage on shares of Certara in a research report on Wednesday, August 24th. They set an outperform rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $26.13.

Certara Price Performance

CERT stock traded up $0.61 during mid-day trading on Thursday, hitting $16.27. The stock had a trading volume of 794,204 shares, compared to its average volume of 670,404. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.28. Certara has a 52 week low of $14.94 and a 52 week high of $45.48. The firm has a market capitalization of $2.60 billion, a P/E ratio of -272.17, a P/E/G ratio of 0.97 and a beta of 1.27. The firm has a fifty day simple moving average of $20.00 and a 200 day simple moving average of $20.16.

Insider Activity

In related news, Director Stephen M. Mclean purchased 20,000 shares of Certara stock in a transaction dated Friday, August 19th. The shares were bought at an average cost of $16.32 per share, for a total transaction of $326,400.00. Following the purchase, the director now owns 42,000 shares in the company, valued at approximately $685,440. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, major shareholder Avatar Parent L.P. Eqt sold 6,004,418 shares of Certara stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $17.38, for a total transaction of $104,356,784.84. Following the sale, the insider now directly owns 29,954,521 shares in the company, valued at approximately $520,609,574.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Stephen M. Mclean bought 20,000 shares of the business's stock in a transaction that occurred on Friday, August 19th. The shares were acquired at an average price of $16.32 per share, for a total transaction of $326,400.00. Following the completion of the transaction, the director now owns 42,000 shares in the company, valued at $685,440. The disclosure for this purchase can be found here. In the last three months, insiders have sold 6,196,893 shares of company stock worth $107,705,300. Corporate insiders own 4.02% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Captrust Financial Advisors lifted its position in shares of Certara by 135.8% in the 1st quarter. Captrust Financial Advisors now owns 4,628 shares of the company's stock worth $99,000 after purchasing an additional 2,665 shares during the period. MetLife Investment Management LLC acquired a new position in shares of Certara in the 1st quarter worth approximately $111,000. PNC Financial Services Group Inc. lifted its position in shares of Certara by 18.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company's stock worth $126,000 after purchasing an additional 905 shares during the period. Atria Wealth Solutions Inc. bought a new stake in shares of Certara in the 1st quarter valued at $218,000. Finally, Hsbc Holdings PLC increased its stake in shares of Certara by 8.5% in the 1st quarter. Hsbc Holdings PLC now owns 11,969 shares of the company's stock valued at $261,000 after acquiring an additional 941 shares in the last quarter. Institutional investors and hedge funds own 77.42% of the company's stock.

Certara Company Profile

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

Featured Stories

• Get a free copy of the StockNews.com research report on Certara (CERT)
• Does Enphase Energy Have the Juice to Keep Powering Higher?
• The One Hydrogen Fuel Cell Stock To Rule Them All
• These Two Undervalued Stocks Are Ready To Rocket Higher
• Are Hidden Gems Lurking Among Chemical & Fertilizer Stocks?
• GameStop Stock Just Flashed A Buy Signal

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.